For the second time in less than a month, a federal court has rejected a pharmaceutical industry lawsuit challenging the drug pricing powers Medicare was granted by the Inflation Reduction Act.
The U.S. District Court for the District of Delaware on Friday rebuffed AstraZeneca’s claims that the authority Medicare received under the IRA is unconstitutional. That decision was issued three weeks after the same court dismissed a suit from The Pharmaceutical Research and Manufacturers of America under the grounds it was filed in the wrong venue.
